At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 315 enrolled
Drug / intervention
mRNA-1647 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults
In Brief
A Phase 2 clinical trial evaluating mRNA-1647 and Placebo for Cytomegalovirus Infection. Completed, enrolled 315 participants across 9 sites.
Detailed Summary
This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCytomegalovirus Infection
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartJan 2020
First PostedJan 2020
Primary CompletionJan 2023
TodayJul 2026
First PostedJan 18, 2020
Enrollment StartJan 9, 2020
Primary CompletionJan 4, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 6.5 years ago
Interventions
mRNA-1647biological
Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
Placeboother
0.9% sodium chloride (normal saline) injection